Thursday, July 14, 2016

Scottish Medicines Consortium (SMC) recommends personalised lung cancer medicine Xalkori® q(crizotinib) for first-line use

… (ALK)-positive advanced non-small cell lung cancer (NSCLC)1. Eligible patients in … give them access to specialist lung cancer treatments, such as Crizotinib.”
Over … innovative medicines to treat eligible lung cancer patients in Scotland. However, patients …

No comments:

Post a Comment